Protein Summary
Poly-ADP-ribosyltransferase involved in various processes such as Wnt signaling pathway, telomere length and vesicle trafficking. Acts as an activator of the Wnt signaling pathway by mediating poly-ADP-ribosylation of AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex: poly-ADP-ribosylated target proteins are recognized by RNF146, which mediates their ubiquitination and subsequent degradation. Also mediates poly-ADP-ribosylation of BLZF1 and CASC3, followed by recruitment of RNF146 and subsequent ubiquitination. Mediates poly-ADP-ribosylation of TERF1, thereby contributing to the regulation of telomere length. May also regulate vesicle trafficking and modulate the subcellular distribution of SLC2A4/GLUT4-vesicles. Stimulates 26S proteasome activity.
- ENST00000371627
- ENSP00000360689
- ENSG00000107854
- PARP5B
- TANK2
- TNKL
- TNKL
- ARTD6
- TANK2
- pART6
- PARP5B
- PARP5C
- PARP-5b
- PARP-5c
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
histone modification site profile | 0.91 | ||
protein domain | 0.85 | ||
cellular component | 0.77 | ||
transcription factor perturbation | 0.74 | ||
transcription factor binding site profile | 0.73 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 172.29 (req: < 5)
Gene RIFs: 37 (req: <= 3)
Antibodies: 209 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 172.29 (req: >= 5)
Gene RIFs: 37 (req: > 3)
Antibodies: 209 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 14
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligands: 547
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drugs: 3